Successful treatment of many cHL patients using antibodies against programmed cell death 1 (PD-1; known as PDCD1) and its ligand (PD-L1; known as CD274) has highlighted the critical importance of PD-1/PD-L1-mediated immune escape in cancer development. Here, PDCD1 is linked to classic Hodgkin lymphoma.